<DOC>
	<DOCNO>NCT01266993</DOCNO>
	<brief_summary>The purpose study evaluate persistence immune response GSK134612 vaccine 68 month vaccination primary vaccination study ( NCT number = NCT00674583 ) 2 10 year old subject . This study also evaluate safety immunogenicity booster dose GSK134612 vaccine subject prim primary vaccination study either GSK134612 vaccine Menjugate® . This protocol post deal objective &amp; outcome measure persistence booster epoch . The objective &amp; outcome measure primary epoch present separate protocol posting ( NCT number = NCT00674583 )</brief_summary>
	<brief_title>Persistence Booster Study GSK Biologicals ' Meningococcal Vaccine ( GSK134612 ) Healthy Children</brief_title>
	<detailed_description>Subjects previously vaccinate 2 10 year age GSK134612 Menjugate® . The persistence phase start 32 month primary vaccination blood sample take 32 , 44 , 56 68 month primary vaccination . All subject receive booster dose GSK134612 68 month primary vaccination blood sample take 1 month administration booster dose .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol enrol study . A male female prim MenACWYTT Menjugate primary vaccination study ( NCT number = NCT00674583 ) . Written inform consent obtain parent ( ) /Legally Acceptable Representatives ( ) subject write informed assent obtain subject ( investigator discretion ) . Healthy subject establish medical history clinical examination enter study . All subject must meet additional follow criterion prior receive booster vaccination : Subjects blood sample take Visit 4 persistence epoch current study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care . Use investigational nonregistered product within 30 day precede first persistence blood sample plan use within 30 day precede blood sample study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug study period . ( For corticosteroid , prednisone &lt; 10 mg/day , equivalent , inhaled topical steroid allow ) . Concurrently participate another clinical study plan participation another clinical study , subject expose investigational noninvestigational product within 30 day blood sample . History meningococcal disease . Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine since previous vaccination primary vaccination study ( NCT number = NCT00674583 ) . Any confirm suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus infection , base medical history physical examination . Serious chronic illness . Administration immunoglobulins and/or blood product within 3 month precede subject 's first visit . Bleeding disorder , thrombocytopenia , subject anticoagulant therapy . Subjects contact somebody suffer invasive infection meningococcal serogroups A , C , Y W135 . Subjects live geographic area local outbreak meningococcal serogroup C occur . Exclusion criterion booster vaccination check Visit 4 ( Month 68 ) Child care . Use investigational nonregistered product within 30 day precede booster vaccination plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior booster vaccination . ( For corticosteroid , prednisone &lt; 10 mg/day , equivalent , inhaled topical steroid allow ) . Vaccination meningococcal polysaccharide conjugate vaccine serogroup A , B , C , W135 , and/or Y since previous vaccination primary vaccination study ( NCT number = NCT00674583 ) . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection , base medical history physical examination . Administration immunoglobulins and/or blood product within three month precede booster vaccination plan administration study period . Concurrently participate another clinical study plan participation another clinical study , time study period , ( time booster end study ) subject expose investigational noninvestigational product . Bleeding disorder , thrombocytopenia , subject anticoagulant therapy . Hypersensitivity latex . Planned administration/ administration vaccine foreseen study protocol within last 30 day dose vaccine ( ) exception license inactivated influenza vaccine . Previous vaccination tetanus toxoid within last 30 day . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History allergic disease reaction likely exacerbate component vaccine . Serious chronic illness . History neurological disorder seizure ( although subject prior history single episode benign febrile seizure may allow participate study ) . Acute disease and/or fever time vaccination . History chronic alcohol consumption and/or drug abuse . History hypotonichyporesponsive episode ( HHEs ) follow vaccination . Subjects contact somebody suffer invasive infection meningococcal serogroups A , C , Y W135 . Subjects live geographic area local outbreak meningococcal serogroup C occur . Pregnant lactate female . Female childbearing potential planning become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Persistence</keyword>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningococcal vaccine</keyword>
</DOC>